Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk - PubMed
2 days ago
- #ischemic optic neuropathy
- #semaglutide
- #drug safety
- Ischemic optic neuropathy (ION) is a rare but serious complication linked to GLP-1 receptor agonists, especially semaglutide.
- Analysis of FDA Adverse Event Reporting System data (2017-2024) found Wegovy had the highest risk for ION (ROR=74.89) compared to Ozempic (ROR=18.81).
- Men showed significantly higher odds of ION (ROR=116.37) than women.
- Multivariable regression confirmed greater risk with Wegovy vs. Ozempic (AOR=4.74) and in men vs. women (AOR=3.33).
- The findings suggest a potential dose-dependent safety concern requiring further evaluation for prescribing and regulatory guidance.